Australia and Oceania: Market for Non-Antibiotic, Non-Hormone, Non-Alkaloid Medicaments For Therapeutic Or Prophylactic Uses 2024

Market Size for Non-Antibiotic, Non-Hormone, Non-Alkaloid Medicaments For Therapeutic Or Prophylactic Uses in Australia and Oceania

In 2023, the market for non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses in Australia and Oceania increased by X% to $X, rising for the second year in a row after two years of decline. Overall, consumption saw strong growth. The level of consumption peaked in 2023 and is likely to see gradual growth in the near future.

Production of Non-Antibiotic, Non-Hormone, Non-Alkaloid Medicaments For Therapeutic Or Prophylactic Uses in Australia and Oceania

In value terms, production of non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses shrank significantly to $X in 2023 estimated in export price. Overall, production continues to indicate a mild slump. The most prominent rate of growth was recorded in 2019 with an increase of X%. As a result, production reached the peak level of $X. From 2020 to 2023, production of growth remained at a lower figure.

Exports of Non-Antibiotic, Non-Hormone, Non-Alkaloid Medicaments For Therapeutic Or Prophylactic Uses

Exports in Australia and Oceania

In 2023, overseas shipments of non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses increased by X% to X tons, rising for the third year in a row after three years of decline. Over the period under review, exports recorded buoyant growth. The pace of growth was the most pronounced in 2022 when exports increased by X% against the previous year. The volume of export peaked in 2023 and is likely to continue growth in the near future.

In value terms, exports of non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses skyrocketed to $X in 2023. Overall, exports continue to indicate resilient growth. The pace of growth appeared the most rapid in 2018 with an increase of X%. As a result, the exports attained the peak of $X. From 2019 to 2023, the growth of the exports of remained at a lower figure.

Exports by Country

Australia (X tons) represented roughly X% of total exports in 2023.

Australia was also the fastest-growing in terms of the non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses exports, with a CAGR of X% from 2012 to 2023. While the share of Australia (X p.p.) increased significantly, the shares of the other countries remained relatively stable throughout the analyzed period.

In value terms, Australia ($X) also remains the largest non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses supplier in Australia and Oceania.

From 2012 to 2023, the average annual rate of growth in terms of value in Australia amounted to X%.

Export Prices by Country

The export price in Australia and Oceania stood at $X per ton in 2023, rising by X% against the previous year. Over the period under review, the export price, however, showed a slight contraction. The growth pace was the most rapid in 2018 an increase of X% against the previous year. Over the period under review, the export prices hit record highs at $X per ton in 2019; however, from 2020 to 2023, the export prices failed to regain momentum.

As there is only one major export destination, the average price level is determined by prices for Australia.

From 2012 to 2023, the rate of growth in terms of prices for Australia amounted to X% per year.

Imports of Non-Antibiotic, Non-Hormone, Non-Alkaloid Medicaments For Therapeutic Or Prophylactic Uses

Imports in Australia and Oceania

In 2023, the amount of non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses imported in Australia and Oceania skyrocketed to X tons, increasing by X% on the previous year. In general, imports showed buoyant growth. The most prominent rate of growth was recorded in 2022 with an increase of X%. The volume of import peaked in 2023 and is likely to continue growth in years to come.

In value terms, imports of non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses reduced to $X in 2023. Overall, imports, however, continue to indicate a pronounced decline. The pace of growth was the most pronounced in 2021 when imports increased by X% against the previous year. The level of import peaked at $X in 2012; however, from 2013 to 2023, imports remained at a lower figure.

Imports by Country

Australia prevails in uses structure, recording X tons, which was approx. X% of total imports in 2023. New Zealand (X tons) took a minor share of total imports.

Australia was also the fastest-growing in terms of the non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses imports, with a CAGR of X% from 2012 to 2023. New Zealand (X%) illustrated a downward trend over the same period. From 2012 to 2023, the share of Australia increased by X percentage points.

In value terms, Australia ($X) constitutes the largest market for imported non-antibiotic, non-hormone, non-alkaloid medicaments for therapeutic or prophylactic uses in Australia and Oceania, comprising X% of total imports. The second position in the ranking was taken by New Zealand ($X), with a X% share of total imports.

From 2012 to 2023, the average annual growth rate of value in Australia stood at X%.

Import Prices by Country

In 2023, the import price in Australia and Oceania amounted to $X per ton, shrinking by X% against the previous year. In general, the import price faced a abrupt downturn. The growth pace was the most rapid in 2021 an increase of X% against the previous year. The level of import peaked at $X per ton in 2012; however, from 2013 to 2023, import prices remained at a lower figure.

Prices varied noticeably by country of destination: amid the top importers, the country with the highest price was New Zealand ($X per ton), while Australia amounted to $X per ton.

From 2012 to 2023, the most notable rate of growth in terms of prices was attained by New Zealand (X%).

Source: IndexBox Platform